Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-05
DOI
10.1038/s41388-018-0581-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chromosomal instability drives metastasis through a cytosolic DNA response
- (2018) Samuel F. Bakhoum et al. NATURE
- Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2017) Shannon Grabosch et al. GYNECOLOGIC ONCOLOGY
- cGAS is essential for cellular senescence
- (2017) Hui Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
- (2016) E. Beyranvand Nejad et al. CANCER RESEARCH
- Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells
- (2016) Chih-Hang Anthony Tang et al. CANCER RESEARCH
- STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
- (2016) Henrique Lemos et al. CANCER RESEARCH
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Immune checkpoint inhibition in ovarian cancer
- (2016) Junzo Hamanishi et al. INTERNATIONAL IMMUNOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death
- (2016) Stefania Di Blasio et al. OncoImmunology
- Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal
- (2015) Ding Liang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model
- (2015) Jyothi Thyagabhavan Mony et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
- (2015) Olivier Demaria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
- (2015) Mingye Feng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Cisplatin in cancer therapy: Molecular mechanisms of action
- (2014) Shaloam Dasari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Tertiary lymphoid structures in cancer and beyond
- (2014) Marie-Caroline Dieu-Nosjean et al. TRENDS IN IMMUNOLOGY
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Immunobiology of human mucin 1 in a preclinical ovarian tumor model
- (2012) R A Budiu et al. ONCOGENE
- BEDTools: a flexible suite of utilities for comparing genomic features
- (2010) Aaron R. Quinlan et al. BIOINFORMATICS
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- (2009) M. D. Robinson et al. BIOINFORMATICS
- UpGene: Application of a Web-Based DNA Codon Optimization Algorithm
- (2004) Wentao Gao et al. BIOTECHNOLOGY PROGRESS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now